RxDoctor Payments Data

Katara Chavis

Family · Pembroke, NCNPI 1245532423

Payments from drug & device makers

$2,035in general payments, 2019–2025

Across 111 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$347
  • AbbVie$278
  • Novo Nordisk$186
  • Amgen$182
  • Idorsia Pharmaceuticals US Inc$134
  • Lilly USA, LLC$122
  • plus $787 from 21 others

What the payments were for

  • Food & beverage$2,035100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,035 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,137
Medicare patients
57
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$155,468
LinzessLinaclotide217$127,583
JardianceEmpagliflozin182$110,084
TrulicityDulaglutide102$100,980
FarxigaDapagliflozin Propanediol141$96,845
MounjaroTirzepatide86$91,151
RelistorMethylnaltrexone Bromide29$74,219
EliquisApixaban117$73,780
KerendiaFinerenone87$55,181
JanuviaSitagliptin Phosphate89$52,988
Tresiba Flextouch U-200Insulin Degludec39$39,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$36,304
Xtampza ErOxycodone Myristate46$36,020
ShingrixVaricella-Zoster Ge/As01b/Pf148$32,660
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog38$22,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$122$192,131188 claims
Novo NordiskOzempic, Rybelsus$186$176,409162 claims
AbbVieLinzess, Restasis, Qulipta$278$156,283251 claims
Boehringer IngelheimJardiance, Synjardy Xr$32$116,566199 claims
AstraZenecaFarxiga, Symbicort$347$115,362217 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$90$74,21929 claims
PfizerEliquis$33$73,780117 claims
BayerKerendia$78$55,18187 claims
NovartisEntresto$31$20,68225 claims
Johnson & JohnsonXarelto$49$10,74219 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$15$10,55212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Pembroke

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →